Imunon (NASDAQ:IMNN) Earns “Buy” Rating from HC Wainwright

Imunon (NASDAQ:IMNN)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a research report issued to clients and investors on Wednesday,Benzinga reports. They currently have a $14.00 price target on the stock.

Separately, D. Boral Capital restated a “buy” rating and issued a $29.00 price target on shares of Imunon in a report on Monday.

Imunon Price Performance

Shares of NASDAQ IMNN opened at $1.14 on Wednesday. Imunon has a 1-year low of $0.64 and a 1-year high of $3.65. The company has a market capitalization of $16.67 million, a price-to-earnings ratio of -0.60 and a beta of 1.96. The business has a 50-day moving average of $0.91 and a 200-day moving average of $0.92.

Hedge Funds Weigh In On Imunon

An institutional investor recently raised its position in Imunon stock. Geode Capital Management LLC lifted its holdings in shares of Imunon, Inc. (NASDAQ:IMNN) by 10.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 139,505 shares of the company’s stock after acquiring an additional 13,570 shares during the quarter. Geode Capital Management LLC owned 0.96% of Imunon worth $133,000 as of its most recent filing with the SEC. 4.47% of the stock is owned by institutional investors and hedge funds.

About Imunon

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.